◀ Back to PIK3CA
HRAS — PIK3CA
Pathways - manually collected, often from reviews:
-
BioCarta fc epsilon receptor i signaling in mast cells:
RAS (HRAS)
→
PI3K complex (PIK3CA-PIK3R1)
(modification, activates)
-
BioCarta role of erbb2 in signal transduction and oncology:
RAS (HRAS)
→
PI3K complex (PIK3CA-PIK3R1)
(modification, activates)
-
KEGG Focal adhesion:
HRAS
→
PIK3CA/PIK3CB/PIK3CD/PIK3CG/PIK3R1/PIK3R2/PIK3R3/PIK3R5
(protein-protein, activation)
-
KEGG Neurotrophin signaling pathway:
HRAS/KRAS/NRAS
→
PIK3CA/PIK3CB/PIK3CD/PIK3CG/PIK3R1/PIK3R2/PIK3R3/PIK3R5
(protein-protein, activation)
-
KEGG Regulation of actin cytoskeleton:
HRAS/KRAS/MRAS/NRAS/RRAS/RRAS2
→
PIK3CA/PIK3CB/PIK3CD/PIK3CG/PIK3R1/PIK3R2/PIK3R3/PIK3R5
(protein-protein, activation)
-
KEGG Pathways in cancer:
HRAS/KRAS/NRAS
→
PIK3CA/PIK3CB/PIK3CD/PIK3CG/PIK3R1/PIK3R2/PIK3R3/PIK3R5
(protein-protein, activation)
-
KEGG Glioma:
HRAS/KRAS/NRAS
→
PIK3CA/PIK3CB/PIK3CD/PIK3CG/PIK3R1/PIK3R2/PIK3R3/PIK3R5
(protein-protein, activation)
-
KEGG Glioma:
HRAS/KRAS/NRAS
→
PIK3CA/PIK3CB/PIK3CD/PIK3CG/PIK3R1/PIK3R2/PIK3R3/PIK3R5
(protein-protein, activation)
-
KEGG Melanoma:
HRAS/KRAS/NRAS
→
PIK3CA/PIK3CB/PIK3CD/PIK3CG/PIK3R1/PIK3R2/PIK3R3/PIK3R5
(protein-protein, activation)
-
KEGG Acute myeloid leukemia:
HRAS/KRAS/NRAS
→
PIK3CA/PIK3CB/PIK3CD/PIK3CG/PIK3R1/PIK3R2/PIK3R3/PIK3R5
(protein-protein, activation)
-
KEGG Chemokine signaling pathway:
PIK3CA/PIK3CB/PIK3CD/PIK3CG/PIK3R1/PIK3R2/PIK3R3/PIK3R5
→
HRAS/KRAS/NRAS
(protein-protein, activation)
-
NCI Pathway Database Trk receptor signaling mediated by PI3K and PLC-gamma:
RAS family/GTP/PI3K complex (PIK3CA-PIK3R1-HRAS_KRAS_HRAS_KRAS_NRAS)
→
TRPV1 (TRPV1)
(modification, activates)
Zhang et al., EMBO J 2005
Evidence: mutant phenotype, physical interaction
-
NCI Pathway Database Trk receptor signaling mediated by PI3K and PLC-gamma:
RAS family/GTP/PI3K complex (PIK3CA-PIK3R1-HRAS_KRAS_HRAS_KRAS_NRAS)
→
Src (SRC)
(modification, activates)
Zhang et al., EMBO J 2005
Evidence: mutant phenotype, physical interaction
-
NCI Pathway Database Trk receptor signaling mediated by PI3K and PLC-gamma:
RAS family/GTP/PI3K complex (PIK3CA-PIK3R1-HRAS_KRAS_HRAS_KRAS_NRAS)
→
None
(modification, activates)
-
NCI Pathway Database Trk receptor signaling mediated by PI3K and PLC-gamma:
RAS family/GTP/PI3K complex (PIK3CA-PIK3R1-HRAS_KRAS_HRAS_KRAS_NRAS)
→
None
(modification, activates)
-
NCI Pathway Database Neurotrophic factor-mediated Trk receptor signaling:
RAS family/GTP/PI3K complex (PIK3CA-PIK3R1-HRAS_KRAS_HRAS_KRAS_NRAS)
→
PI3K complex (PIK3CA-PIK3R1)
(modification, collaborate)
Rodriguez-Viciana et al., Nature 1994
Evidence: mutant phenotype, physical interaction
-
NCI Pathway Database Neurotrophic factor-mediated Trk receptor signaling:
RAS family/GTP/PI3K complex (PIK3CA-PIK3R1-HRAS_KRAS_HRAS_KRAS_NRAS)
→
RAS family/GTP complex (HRAS_KRAS_HRAS_KRAS_NRAS)
(modification, collaborate)
Rodriguez-Viciana et al., Nature 1994
Evidence: mutant phenotype, physical interaction
-
NCI Pathway Database Neurotrophic factor-mediated Trk receptor signaling:
PI3K complex (PIK3CA-PIK3R1)
→
RAS family/GTP complex (HRAS_KRAS_HRAS_KRAS_NRAS)
(modification, collaborate)
Rodriguez-Viciana et al., Nature 1994
Evidence: mutant phenotype, physical interaction
-
WikiPathways Focal Adhesion-PI3K-Akt-mTOR-signaling pathway:
NRAS/KRAS/HRAS
→
PIK3CA/PIK3R1/PIK3IP1/PIK3R2/PIK3CB/PIK3CD/PIK3R4
(activation)
-
WikiPathways Human Thyroid Stimulating Hormone (TSH) signaling pathway:
PIK3CA
→
HRAS
(activation)
-
WikiPathways PI3K-AKT-mTOR signaling pathway and therapeutic opportunities:
HRAS/NRAS/KRAS
→
Complex of PIK3CA-PIK3CB-PIK3R1-PIK3R2-PIK3R3-PIK3CG
(activation)
-
WikiPathways Pathways Affected in Adenoid Cystic Carcinoma:
HRAS
→
PIK3CA
(activation)
-
WikiPathways Chemokine signaling pathway:
PIK3CA/PIK3CD/PIK3R1/PIK3R2/PIK3R3/PIK3CG/PIK3R5/PIK3CB
→
HRAS/KRAS/NRAS
(activation)
Protein-Protein interactions - manually collected from original source literature:
Studies that report less than 10 interactions are marked with *
-
IRef Bind_translation Interaction:
PIK3CA
—
HRAS
(affinity chromatography technology)
Rodriguez-Viciana et al., EMBO J 1996*, Rodriguez-Viciana et al., Cell 1997*
-
IRef Bind_translation Interaction:
PIK3CA
—
HRAS
(coimmunoprecipitation)
Rodriguez-Viciana et al., Nature 1994, Rodriguez-Viciana et al., Cell 1997*
-
IRef Biogrid Interaction:
PIK3CA
—
HRAS
(direct interaction, pull down)
Vargiu et al., Oncogene 2004*
-
IRef Biogrid Interaction:
PIK3CA
—
HRAS
(direct interaction, two hybrid)
Li et al., Genes Dev 2000
-
IRef Biogrid Interaction:
PIK3CA
—
HRAS
(direct interaction, pull down)
Rodriguez-Viciana et al., EMBO J 1996*
-
IRef Hprd Interaction:
PIK3CA
—
HRAS
(in vivo)
Rodriguez-Viciana et al., Cell 1997*
-
IRef Ophid Interaction:
PIK3CA
—
HRAS
(aggregation, interologs mapping)
Brown et al., Bioinformatics 2005
Text-mined interactions from Literome
Madrid et al., Mol Cell Biol 2000
:
In this study, we show that oncogenic
H-Ras requires
PI3K and Akt to stimulate the transcriptional activity of NF-kappaB
Guillemot et al., J Biol Chem 2001
(MAP Kinase Signaling System) :
Taken together, these findings demonstrate that Ang II-induced cyclin D1 up-regulation is mediated by the activation and specific interaction of Egr-1 with the -136 to -96 bp region of the cyclin D1 promoter and by activation of the -29 to +139 bp region, both in a
p21(ras)/Raf-1/MEK/ERK dependent manner, and also involves
PI3K and SHP-2
Weber et al., Mol Biol Cell 2001
:
Our data suggest that inhibition of initial
PI3-K activation by inactive
H-Ras or sustained activation of an inhibitory ERK pathway by active H-Ras prevail to abolish LFA-1 regulation and transendothelial migration induced by SDF-1alpha in leukocytes, establishing a complex and bimodal involvement of H-Ras
Choi et al., Oncogene 2004
:
Taken together, these findings explain the opposite effects of Ha-Ras and Ki-Ras on modulation of radiosensitivity, and suggest that differential
activation of
PI3K/Akt and Rac/p38 MAPK signaling by
Ha-Ras and Ki-Ras may account for the opposing response to the ionizing radiation
Carón et al., Mol Cancer Ther 2005
(Carcinoma...) :
In HCT116 cells expressing H-RAS V12, PI3K dependent radioresistance is mediated by both
H-RAS dependent translocation of
PI3K into the plasma membrane and heregulin induced activation of membrane localized PI3K via ERBB3
Carón et al., Mol Cancer Ther 2005
(Carcinoma...) :
Activated forms of
H-RAS and K-RAS differentially
regulate membrane association of
PI3K , PDK-1, and AKT and the effect of therapeutic kinase inhibitors on cell survival
David et al., J Immunol 2005
:
In that pharmacological inhibitors of
PI3K inhibited LPS induced activation of
p21Ras , but not activation of ERK, we concluded that LPS induced activation of ERK occurs through a pathway that is not dependent on the activation of p21Ras
Forti et al., An Acad Bras Cienc 2006
(Adrenal Cortex Neoplasms...) :
We previously reported that this genetic lesion leads to high constitutive levels of
activation of the
c-Ki-Ras-GTP -- >
PI3K -- > Akt signaling pathway ( Forti et al. 2002 )
Yoon et al., Mol Cancer Ther 2006
(Breast Neoplasms...) :
H-Ras did not increase MMP-9 in the
presence of a
PI3K inhibitor, LY294002, and a NF-kappaB inhibitor, SN50
Fivaz et al., Curr Biol 2008
:
Here, we use live FRET imaging in hippocampal neurons and show that the activity of the small
GTPase HRas , an upstream
regulator of
PI3K , markedly increases in the nascent axonal growth cone upon symmetry breaking